Evaluating the effectiveness of the universal immunization program against varicella in Japanese children

Nagoya VZV study group

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective Matched case control study was conducted to elucidate the effectiveness of the Oka/Biken vaccine immediately after implementation of the universal immunization program in Japan. Methods Cases were laboratory confirmed varicella patient under 15 years of age diagnosed at 14 designated pediatric clinics between September 2015 and September 2016. Controls were selected from patients who visited the same practice for different reasons as the varicella case within 2 weeks. Swab samples were collected from varicella suspected patients and molecular diagnostic assays were used to confirm varicella cases. Matched odds ratio were used to calculate vaccine effectiveness (VE). Results Varicella zoster virus DNA was detected in 183 (81.3%) of 225 suspected cases. One sample was excluded because it was positive for the Oka vaccine strain (182/225, 80.9%). Three hundred twenty-three control subjects were enrolled. The effectiveness of 1 dose of the Oka/Biken vaccine compared with no vaccine was 76.7% (95% confidence interval [CI]: 58.6–86.9%; P < 0.001). The effectiveness of 2 doses of the Oka/Biken vaccine was 94.2% (95% CI: 85.7–97.6%; P < 0.001). After adjusting for potential confounding effects, the adjusted VE of 1 and 2 doses of varicella vaccine were 76.9% (95% CI: 58.1–87.3%; P < 0.001) and 94.7% (95% CI: 86.0–98.0%; P < 0.001), respectively. Conclusions VE of one dose of Oka/Biken varicella vaccine was insufficient to control varicella. Therefore, two doses of Oka/Biken varicella vaccine is significant for controlling varicella in Japan.

Original languageEnglish
Pages (from-to)4936-4941
Number of pages6
JournalVaccine
Volume35
Issue number37
DOIs
Publication statusPublished - 05-09-2017

Fingerprint

Immunization Programs
Chickenpox
immunization
Vaccines
vaccines
Chickenpox Vaccine
Confidence Intervals
confidence interval
dosage
Japan
Human Herpesvirus 3
Molecular Pathology
Human herpesvirus 3
Case-Control Studies
Odds Ratio
case-control studies
Pediatrics
odds ratio
DNA

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

@article{ddeaa25ea60647be9dee46f6dbe4197d,
title = "Evaluating the effectiveness of the universal immunization program against varicella in Japanese children",
abstract = "Objective Matched case control study was conducted to elucidate the effectiveness of the Oka/Biken vaccine immediately after implementation of the universal immunization program in Japan. Methods Cases were laboratory confirmed varicella patient under 15 years of age diagnosed at 14 designated pediatric clinics between September 2015 and September 2016. Controls were selected from patients who visited the same practice for different reasons as the varicella case within 2 weeks. Swab samples were collected from varicella suspected patients and molecular diagnostic assays were used to confirm varicella cases. Matched odds ratio were used to calculate vaccine effectiveness (VE). Results Varicella zoster virus DNA was detected in 183 (81.3{\%}) of 225 suspected cases. One sample was excluded because it was positive for the Oka vaccine strain (182/225, 80.9{\%}). Three hundred twenty-three control subjects were enrolled. The effectiveness of 1 dose of the Oka/Biken vaccine compared with no vaccine was 76.7{\%} (95{\%} confidence interval [CI]: 58.6–86.9{\%}; P < 0.001). The effectiveness of 2 doses of the Oka/Biken vaccine was 94.2{\%} (95{\%} CI: 85.7–97.6{\%}; P < 0.001). After adjusting for potential confounding effects, the adjusted VE of 1 and 2 doses of varicella vaccine were 76.9{\%} (95{\%} CI: 58.1–87.3{\%}; P < 0.001) and 94.7{\%} (95{\%} CI: 86.0–98.0{\%}; P < 0.001), respectively. Conclusions VE of one dose of Oka/Biken varicella vaccine was insufficient to control varicella. Therefore, two doses of Oka/Biken varicella vaccine is significant for controlling varicella in Japan.",
author = "{Nagoya VZV study group} and Fumihiko Hattori and Hiroki Miura and Ken Sugata and Akiko Yoshikawa and Masaru Ihira and Yuichiro Yahata and Hajime Kamiya and Keiko Tanaka-Taya and Tetsushi Yoshikawa",
year = "2017",
month = "9",
day = "5",
doi = "10.1016/j.vaccine.2017.07.090",
language = "English",
volume = "35",
pages = "4936--4941",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "37",

}

Evaluating the effectiveness of the universal immunization program against varicella in Japanese children. / Nagoya VZV study group.

In: Vaccine, Vol. 35, No. 37, 05.09.2017, p. 4936-4941.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Evaluating the effectiveness of the universal immunization program against varicella in Japanese children

AU - Nagoya VZV study group

AU - Hattori, Fumihiko

AU - Miura, Hiroki

AU - Sugata, Ken

AU - Yoshikawa, Akiko

AU - Ihira, Masaru

AU - Yahata, Yuichiro

AU - Kamiya, Hajime

AU - Tanaka-Taya, Keiko

AU - Yoshikawa, Tetsushi

PY - 2017/9/5

Y1 - 2017/9/5

N2 - Objective Matched case control study was conducted to elucidate the effectiveness of the Oka/Biken vaccine immediately after implementation of the universal immunization program in Japan. Methods Cases were laboratory confirmed varicella patient under 15 years of age diagnosed at 14 designated pediatric clinics between September 2015 and September 2016. Controls were selected from patients who visited the same practice for different reasons as the varicella case within 2 weeks. Swab samples were collected from varicella suspected patients and molecular diagnostic assays were used to confirm varicella cases. Matched odds ratio were used to calculate vaccine effectiveness (VE). Results Varicella zoster virus DNA was detected in 183 (81.3%) of 225 suspected cases. One sample was excluded because it was positive for the Oka vaccine strain (182/225, 80.9%). Three hundred twenty-three control subjects were enrolled. The effectiveness of 1 dose of the Oka/Biken vaccine compared with no vaccine was 76.7% (95% confidence interval [CI]: 58.6–86.9%; P < 0.001). The effectiveness of 2 doses of the Oka/Biken vaccine was 94.2% (95% CI: 85.7–97.6%; P < 0.001). After adjusting for potential confounding effects, the adjusted VE of 1 and 2 doses of varicella vaccine were 76.9% (95% CI: 58.1–87.3%; P < 0.001) and 94.7% (95% CI: 86.0–98.0%; P < 0.001), respectively. Conclusions VE of one dose of Oka/Biken varicella vaccine was insufficient to control varicella. Therefore, two doses of Oka/Biken varicella vaccine is significant for controlling varicella in Japan.

AB - Objective Matched case control study was conducted to elucidate the effectiveness of the Oka/Biken vaccine immediately after implementation of the universal immunization program in Japan. Methods Cases were laboratory confirmed varicella patient under 15 years of age diagnosed at 14 designated pediatric clinics between September 2015 and September 2016. Controls were selected from patients who visited the same practice for different reasons as the varicella case within 2 weeks. Swab samples were collected from varicella suspected patients and molecular diagnostic assays were used to confirm varicella cases. Matched odds ratio were used to calculate vaccine effectiveness (VE). Results Varicella zoster virus DNA was detected in 183 (81.3%) of 225 suspected cases. One sample was excluded because it was positive for the Oka vaccine strain (182/225, 80.9%). Three hundred twenty-three control subjects were enrolled. The effectiveness of 1 dose of the Oka/Biken vaccine compared with no vaccine was 76.7% (95% confidence interval [CI]: 58.6–86.9%; P < 0.001). The effectiveness of 2 doses of the Oka/Biken vaccine was 94.2% (95% CI: 85.7–97.6%; P < 0.001). After adjusting for potential confounding effects, the adjusted VE of 1 and 2 doses of varicella vaccine were 76.9% (95% CI: 58.1–87.3%; P < 0.001) and 94.7% (95% CI: 86.0–98.0%; P < 0.001), respectively. Conclusions VE of one dose of Oka/Biken varicella vaccine was insufficient to control varicella. Therefore, two doses of Oka/Biken varicella vaccine is significant for controlling varicella in Japan.

UR - http://www.scopus.com/inward/record.url?scp=85026776746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026776746&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2017.07.090

DO - 10.1016/j.vaccine.2017.07.090

M3 - Article

C2 - 28784281

AN - SCOPUS:85026776746

VL - 35

SP - 4936

EP - 4941

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 37

ER -